115 results
8-K
EX-10.1
WINT
Windtree Therapeutics Inc
16 Oct 18
Entry into a Material Definitive Agreement
4:40pm
OR FACILITY. IF YOU FIND THE TERMS AND CONDITIONS OF THIS STANDBY LETTER OF CREDIT AMENDMENT UNACCEPTABLE, PLEASE CONTACT YOUR CUSTOMER (THE APPLICANT
8-K
EX-99.2
WINT
Windtree Therapeutics Inc
24 Oct 12
Other Events
12:00am
prior to customer interaction with DSCO field team Very/ Likely to Advocate Surfaxin Recent Market Survey: High Interest in SURFAXIN® Favorable Baseline
8-K
EX-2.4
gjdpi3r1
21 Jul 97
Other events
12:00am
8-K
EX-10.1
5r6sevu70e
22 Oct 03
Other events
12:00am
8-K
EX-2.1
y6ckxxjitqo77 kmro
21 Jul 97
Other events
12:00am
8-K
EX-10.2
60k ecik3
26 Oct 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
vq61 hz9a4x6ir7e10
3 Jan 06
Represents strategic decision to control manufacturing of Surfaxinâ and SRT pipeline
12:00am
424B3
0mw4nrr47hopp
11 Jul 08
Prospectus supplement
12:00am
S-1/A
EX-10.50
p497klo
6 May 20
IPO registration (amended)
5:31pm
424B3
kg3add4mcmqbi
9 Apr 09
Prospectus supplement
12:00am
424B3
jyxlornh z98
15 Jun 10
Prospectus supplement
12:00am